- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | BridgeBio Oncology presents preclinical data on KRAS inhibitor | 10 | Investing.com | ||
| BRIDGEBIO ONCOLOGY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.04. | TheRas, Inc. (d/b/a BBOT): BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 22.04. | BridgeBio Oncology names Pedro Beltran as new CEO | 1 | Investing.com | ||
| 22.04. | BridgeBio Oncology Therapeutics appoints new CEO and COO | 3 | Seeking Alpha | ||
| 22.04. | TheRas, Inc. (d/b/a BBOT): BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman | 212 | GlobeNewswire (Europe) | Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development... ► Artikel lesen | |
| 21.04. | BridgeBio Oncology presents preclinical data on BBO-10203 | 1 | Investing.com | ||
| 21.04. | TheRas, Inc. (d/b/a BBOT): BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 20.04. | BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset | 3 | Seeking Alpha | ||
| 20.04. | TheRas, Inc. (d/b/a BBOT): BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma | 110 | GlobeNewswire (Europe) | BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected... ► Artikel lesen | |
| 13.04. | TheRas, Inc. (d/b/a BBOT): BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 26.03. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | TheRas, Inc. (d/b/a BBOT): BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| 06.03. | BBOT publishes preclinical data on panKRAS inhibitor BBO-11818 | 2 | Investing.com | ||
| 06.03. | BridgeBio Oncology Therapeutics veröffentlicht präklinische Daten zu panKRAS-Inhibitor BBO-11818 | 1 | Investing.com Deutsch | ||
| 06.03. | TheRas, Inc. (d/b/a BBOT): BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor | 3 | GlobeNewswire (USA) | ||
| 06.03. | Stifel reiterates Buy on BridgeBio Oncology stock, $23 target | 2 | Investing.com | ||
| 06.03. | BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$0.49 | 1 | Seeking Alpha | ||
| 05.03. | BridgeBio Oncology Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,065 | -25,17 % | Summit Therapeutics Inc. - 10-Q, Quarterly Report | ||
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| ERASCA | 10,360 | -2,63 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 329,55 | +3,45 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| EVOTEC | 5,240 | +4,70 % | EQS-News: Evotec SE: Evotec kündigt Wechsel im Finanzvorstand an | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec kündigt Wechsel im Finanzvorstand an
24.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,340 | +2,15 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| MINERALYS THERAPEUTICS | 28,660 | +7,58 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| CG ONCOLOGY | 66,12 | -0,94 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,050 | -2,23 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| RECURSION PHARMACEUTICALS | 3,460 | -0,14 % | Recursion Pharmaceuticals: Recursion Announces Board Transition | Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,200 | +1,26 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,750 | +5,38 % | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | ~1.35 million total VOQUEZNA prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,980 | +2,21 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| LAKEWOOD-AMEDEX BIOTHERAPEUTICS | 3,490 | +33,72 % | Lakewood-Amedex reports resistance data for diabetic ulcer drug |
BRIDGEBIO ONCOLOGY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,300 Euro und damit -0,72 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRIDGEBIO ONCOLOGY THERAPEUTICS INC finden Sie auf Wallstreet Online.